Overexpression of microRNA-133b reduces myocardial injuries in children with viral myocarditis by targeting Rab27B

Y Zhang1, L Sun1, H Sun2

  • 1Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430000, P.R. China.

Insights

Reduced microRNA-133b (miR-133b) in children with viral myocarditis correlates with heart injury. Restoring miR-133b levels alleviates viral myocarditis by targeting Rab27B, reducing inflammation and cardiomyocyte damage.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pediatrics

Background:

  • Viral myocarditis is a serious condition in children.
  • MicroRNAs play crucial roles in cardiovascular diseases.
  • Understanding molecular mechanisms is key to effective treatment.

Purpose of the Study:

  • To measure miR-133b levels in children with viral myocarditis.
  • To investigate the relationship between miR-133b and myocardial injury severity.
  • To explore the therapeutic potential of miR-133b in viral myocarditis.

Main Methods:

  • Quantitative real-time polymerase chain reaction for miR-133b expression.
  • CCK-8 assay for cardiomyocyte proliferation.
  • ELISA and Western blotting for inflammatory markers (TNF-α, IL-6) and cardiac enzymes (CK-MB, LDH).
  • Bioinformatics and dual luciferase reporter assay to identify and validate miR-133b targets (Rab27B).

Main Results:

  • miR-133b expression was significantly reduced in children with viral myocarditis and in CVB3-infected cardiomyocytes.
  • Reduced miR-133b levels correlated with myocardial injury severity.
  • Overexpression of miR-133b inhibited CVB3-induced cardiomyocyte injury, inflammation (TNF-α, IL-6), and proliferation.
  • miR-133b directly targets Rab27B, and Rab27B promotes CVB3-induced cardiomyocyte injury.

Conclusions:

  • Circulating miR-133b is a potential biomarker for viral myocarditis severity in children.
  • miR-133b exerts protective effects against viral myocarditis by targeting Rab27B.
  • Modulating miR-133b levels offers a promising therapeutic strategy for viral myocarditis.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
228
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K